Home › Compare › OIEXF vs JNJ

OIEXF vs JNJ: Dividend Comparison 2026

OIEXF yields 222222.22% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OIEXF wins by $1.4076447531278624e+30M in total portfolio value
10 years
OIEXF
OIEXF
● Live price
222222.22%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.4076447531278624e+30M
Annual income
$1,406,399,782,569,334,400,000,000,000,000,000,000.00
Full OIEXF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — OIEXF vs JNJ

📍 OIEXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOIEXFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OIEXF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
OIEXF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OIEXF
Annual income on $10K today (after 15% tax)
$18,888,888.89/yr
After 10yr DRIP, annual income (after tax)
$1,195,439,815,183,934,200,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, OIEXF beats the other by $1,195,439,815,183,934,200,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OIEXF + JNJ for your $10,000?

OIEXF: 50%JNJ: 50%
100% JNJ50/50100% OIEXF
Portfolio after 10yr
$7.038223765639312e+29M
Annual income
$703,199,891,284,667,200,000,000,000,000,000,000.00/yr
Blended yield
99.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

OIEXF
No analyst data
Altman Z
-13.6
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OIEXF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOIEXFJNJ
Forward yield222222.22% ✓2.13%
Annual dividend / share$2.00$5.20 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28% ✓
Portfolio after 10y$1.4076447531278624e+30M$30.3K ✓
Annual income after 10y$1,406,399,782,569,334,400,000,000,000,000,000,000.00 ✓$4,689.40
Total dividends collected$1.4075632434891558e+30M$15.4K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OIEXF vs JNJ ($10,000, DRIP)

YearOIEXF PortfolioOIEXF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$22,232,922$22,222,222.22$10,592$272.30+$22.22M → OIEXF
2$46,198,082,523$46,174,293,296.41$11,289$357.73+$46198.07M → OIEXF
3$89,718,752,943,223$89,669,320,994,923.30$12,123$472.89+$89718752.93M → OIEXF
4$162,845,393,609,755,680$162,749,394,544,106,430.00$13,141$629.86+$162845393609.74M → OIEXF
5$276,249,735,879,778,500,000$276,075,491,308,616,120,000.00$14,408$846.81+$276249735879778.50M → OIEXF
6$437,989,462,258,048,500,000,000$437,693,875,040,657,100,000,000.00$16,021$1,151.60+$437989462258048512.00M → OIEXF
7$649,026,142,700,674,900,000,000,000$648,557,493,976,058,700,000,000,000.00$18,122$1,588.22+$649026142700674875392.00M → OIEXF
8$898,874,153,179,794,200,000,000,000,000$898,179,695,207,104,400,000,000,000,000.00$20,930$2,228.20+$8.988741531797941e+23M → OIEXF
9$1,163,523,886,474,633,300,000,000,000,000,000$1,162,562,091,130,731,000,000,000,000,000,000.00$24,792$3,191.91+$1.1635238864746333e+27M → OIEXF
10$1,407,644,753,127,862,300,000,000,000,000,000,000$1,406,399,782,569,334,400,000,000,000,000,000,000.00$30,274$4,689.40+$1.4076447531278624e+30M → OIEXF

OIEXF vs JNJ: Complete Analysis 2026

OIEXF — Stock

Synergia Energy Ltd engages in the exploration for, appraisal, development, production, and sale of oil and gas in Australia, India, and Indonesia. It primarily holds 100% interest in the Cambay field located in the Cambay basin, onshore Gujarat, India. The company was formerly known as Oilex Ltd and changed its name to Synergia Energy Ltd in July 2022. The company was incorporated in 1997 and is headquartered in West Perth, Australia.

Full OIEXF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this OIEXF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OIEXF vs SCHDOIEXF vs JEPIOIEXF vs OOIEXF vs KOOIEXF vs MAINOIEXF vs ABBVOIEXF vs MRKOIEXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.